BioCryst to Present at Upcoming Investor Conferences

Rhea-AI Summary

BioCryst Pharmaceuticals (Nasdaq: BCRX) announced its participation in several upcoming virtual investor conferences. Notable events include the 2021 Jefferies London Healthcare Conference on November 18, the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22, the Evercore ISI HeathCONx Conference on December 1, and the JMP Securities Hematology and Oncology Summit on December 6. Links to live audio webcasts and replays will be available on BioCryst's website. The company focuses on developing innovative medicines for rare diseases.

RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the following upcoming virtual investor conferences:

• 2021 Jefferies London Healthcare Conference—pre-recorded fireside chat available beginning Thursday, November 18 at 3:00 a.m. ET
  
  
• Piper Sandler 33rd Annual Virtual Healthcare Conference—pre-recorded fireside chat available beginning Monday, November 22 at 10 a.m. ET
  
  
• 4th Annual Evercore ISI HeathCONx Conference on Wednesday, December 1 at 3:05 p.m. ET
  
  
• JMP Securities Hematology and Oncology Summit on Monday, December 6 at 1:00 p.m. ET

Links to the live audio webcast of the Evercore and JMP presentations, and replays of all presentations, may be accessed in the Investors section of BioCryst’s website at http://www.biocryst.com.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO® (berotralstat) is approved in the United States, the European Union, Japan, the United Arab Emirates and the United Kingdom. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB® (peramivir injection) has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the company’s website at www.biocryst.com.

BCRXW

Investors:
John Bluth
+1 919 859 7910
jbluth@biocryst.com

Media:
Catherine Collier Kyroulis
+1 917 886 5586
ckyroulis@biocryst.com

FAQ

When is BioCryst Pharmaceuticals presenting at the Jefferies London Healthcare Conference?

BioCryst Pharmaceuticals will present at the Jefferies London Healthcare Conference on November 18, 2021.

What are the dates for the upcoming investor conferences for BCRX?

The upcoming investor conferences for BioCryst (BCRX) are on November 18, November 22, December 1, and December 6, 2021.

How can I access the live presentations of BioCryst's upcoming conferences?

Links to the live audio webcasts of BioCryst's upcoming presentations can be accessed on their official website in the Investors section.

What is the focus of BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals focuses on discovering innovative, oral medicines for rare diseases, targeting significant unmet medical needs.

What is the ticker symbol for BioCryst Pharmaceuticals?

The stock symbol for BioCryst Pharmaceuticals is BCRX.